KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Sales (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Return on Sales for 16 consecutive years, with 0.31% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales fell 77.0% to 0.31% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.23%, a 21.0% decrease, with the full-year FY2025 number at 0.23%, down 21.0% from a year prior.
  • Return on Sales was 0.31% for Q4 2025 at Halozyme Therapeutics, down from 0.49% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.67% in Q2 2021 to a low of 0.69% in Q3 2021.
  • A 5-year average of 0.32% and a median of 0.39% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: tumbled -125bps in 2021, then surged 99bps in 2022.
  • Halozyme Therapeutics' Return on Sales stood at 0.65% in 2021, then crashed by -51bps to 0.32% in 2022, then grew by 17bps to 0.37% in 2023, then increased by 24bps to 0.46% in 2024, then plummeted by -168bps to 0.31% in 2025.
  • Per Business Quant, the three most recent readings for HALO's Return on Sales are 0.31% (Q4 2025), 0.49% (Q3 2025), and 0.51% (Q2 2025).